Attovia Therapeutics
Founded 2023 · 54 employees on LinkedIn · 8 known investors
Find your way into Attovia Therapeutics
1,797 people in our graph share verified history with the Attovia Therapeutics team — schools, employers, funds. One of them is your warm intro.
Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options. Its team includes a leadership team, board of directors, and scientific advisors experienced in drug development and company building.
Founders & leadership
Attovia Therapeutics was founded in 2023 by Zaneta Odrowaz, Tao Fu, MBA, M.S., Zaneta Odrowaz, Ph.D., Petter Veiby, and Hangjun Zhan, Ph.D..
Investors · 8
Competitors · 2
by search overlap
Companies competing with Attovia Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Goldman Sachs-backed biopharma company Attovia Therapeutics files for US IPOpharma.economictimes.indiatimes.com · Jul 2026
Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno - BioSpacebiospace.com · Jul 2026
Braveheart, Attovia join next wave of biotech IPOs | BioPharma Divebiopharmadive.com · Jul 2026
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixentfiercebiotech.com · Jul 2026Frequently asked questions
- What does Attovia Therapeutics do?
- Attovia is a biotechnology company focused on drug development and clinical strategy, aiming to bring treatments to patients where none exist and create next-generation therapeutic options. Its team includes a leadership team, board of directors, and scientific advisors experienced in drug development and company building.
- Who founded Attovia Therapeutics?
- Attovia Therapeutics was founded by Zaneta Odrowaz, Tao Fu, MBA, M.S., Zaneta Odrowaz, Ph.D., Petter Veiby, Hangjun Zhan, Ph.D. in 2023.
- Who are Attovia Therapeutics's investors?
- Attovia Therapeutics's investors include EcoR1 Capital, Frazier Life Sciences, Illumina Ventures, Nextech Invest, Sanofi Ventures, Vida Ventures, Goldman Sachs, venBio Partners.